Ascentage Pharma Group Inc.
Clinical trials sponsored by Ascentage Pharma Group Inc., explained in plain language.
Biopharmaceutical company developing targeted cancer therapies.
Trade on eToro (ad)Not investment advice. Company information is shown for context only. Clinical trials frequently fail.
-
New pill shows promise for Hard-to-Treat blood cancers
Disease control OngoingThis early-stage trial is testing an experimental oral drug called APG-2575 in people with relapsed or refractory chronic lymphocytic leukemia (CLL) and non-Hodgkin lymphoma (NHL). The main goal is to check the drug's safety and find the best dose. About 74 participants will take…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 12:28 UTC
-
New combo tackles Drug-Resistant lung cancer
Disease control OngoingThis early-phase trial tests a new drug called APG-1252 combined with the standard pill osimertinib in 80 people with EGFR-positive non-small cell lung cancer that has stopped responding to other targeted therapies. The goal is to find a safe dose and see if the combination can s…
Phase: PHASE1 • Sponsor: Ascentage Pharma Group Inc. • Aim: Disease control
Last updated Jun 27, 2026 07:53 UTC